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Key Points
•GBIs are measurable
elements for quality of
care and are currently
lacking for adult MDS
patients.
•We developed a GBI
consensus for the
domains of diagnosis
(n 5 14), therapy
(n 5 8), and provider/
infrastructural charac-
teristics (n 5 7).
Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem
cell disorders with an increasing burden on health care systems. Evidence-based MDS
guidelines and recommendations (G/Rs) are published but do not necessarily translate into
better quality of care if adherence is not maintained in daily clinical practice. Guideline-
based indicators (GBIs) are measurable elements for the standardized assessment of quality
of care and, thus far, have not been developed for adult MDS patients. To this end, we
screened relevant G/Rs published between 1999 and 2018 and aggregated all available
information as candidate GBIs into a formalized handbook as the basis for the subsequent
consensus rating procedure. An international multidisciplinary expert panel group (EPG)
of acknowledged MDS experts (n 5 17), health professionals (n 5 7), and patient advocates
(n 5 5) was appointed. The EPG feedback rates for the first and second round were 82% (23 of
28) and 96% (26 of 27), respectively. A final set of 29 GBIs for the 3 domains of diagnosis (n5 14),
therapy (n 5 8), and provider/infrastructural characteristics (n 5 7) achieved the predefined
agreement score for selection (.70%). We identified shortcomings in standardization of
Submitted 14 May 2020; accepted 29 June 2020; published online 25 August 2020.
DOI 10.1182/bloodadvances.2020002314.
*K.S. and T.S. contributed equally to this work.
Preliminary data presented in abstract form at the 61st annual meeting of the American
Society of Hematology, Orlando, FL, 7-10 December 2019 (abstract 4752) and 25th
annual meeting of the European Hematology Association, Frankfurt, Germany, virtual
edition 11-21 June 2020 (abstract EP808).
Data-sharing requests may be e-mailed to the corresponding author, Nicolas Bonadies,
at nicolas.bonadies@insel.ch.
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
25 AUGUST 2020 x VOLUME 4, NUMBER 16 4029
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
6
1
5
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
patient-reported outcomes, toxicity, and geriatric assessments that need to be optimized in
the future. Our GBIs represent the first comprehensive consensus on measurable elements
addressing best practice performance, outcomes, and structural resources. They can be used as
a standardized instrument with the goal of assessing, comparing, and fostering good quality of
care within clinical development cycles in the daily care of adult MDS patients.
Introduction
Publishing guidelines and recommendations (G/Rs) does not
necessarily translate into better quality of care if they are not
implemented and adherence is not maintained in daily clinical
practice.1,2 Adherence to G/Rs is considered a cornerstone for
appropriate health service with proven benefit for patients and health care
systems.3-5 Moreover, appropriate care is fundamental to counteract
potential negative consequences for patients and society in economically
driven health care systems.6 To this end, standardized assessment tools
for practice performance, outcomes, and structural resources are
required to measure, compare, and improve quality in health care
systems using clinical development cycles.7,8 However, this is not
systematically done in daily care, mainly due to a lack of consensus on
clinically relevant and measurable elements for quality of care. Hence,
quality indicators are being developed for a variety of malignancies in
regional and national quality assurance consensus programs such as
the Quality Oncology Practice Initiative (QOPI) program initiated by
the American Society of Clinical Oncology (ASCO).9,10 These programs
focus mainly on solid tumors or lymphoma,11-14 but quality
indicators addressing hematological neoplasms, such as myelo-
dysplastic syndromes (MDSs), have thus far not been developed.
MDSs represent a heterogeneous group of hematological stem
cell neoplasms with a variable risk of transformation into second-
ary acute myeloid leukemia (AML). MDSs are characterized by
cytopenia, dysplasia, and inflammation and occur in all age groups
with a median age of onset above 70 years.15,16 Due to the aging of
the general population, improvements in diagnostics, and increas-
ing survivorship of other cancers, resulting in populations at higher
risks for secondary malignancies, MDS is an emerging disease with
an increasing burden on health care systems.17,18 The heteroge-
neity of the disease, multimorbidity of the elderly patients, and
increasing diagnostic as well as therapeutic options put patients
and health care systems at risk for inappropriate use of medical
interventions, endangering good quality of care. Several national and
international evidence-based guidelines for diagnosis, prognosis, and
therapy of adult MDSs have been published to assist and legitimize
clinicians in their daily decision-making. Retrospective studies have
identified shortcomings in the diagnostic workup and treatment of
MDS patients, but the degree of adherence, the reasons for
nonadherence and the impact on outcomes remain unknown.19
Quality indicators are defined as “measurable elements of practice
performance for which there is evidence or consensus that they can
be used to assess and change the quality of care provided.”3(p104)
Quality indicators are usually extracted from published, evidence-
based guidelines by a structured selection and consensus process
and are referred to as guideline-based indicators (GBIs).20,21 GBIs
have to be relevant, understandable, measurable, behavior oriented,
and attainable (RUMBA criteria) and allow process-based
quality of care with impact on patient-centered outcomes to be
operationalized.22 GBIs have not been developed for patients
with hematological neoplasms, including MDSs. This lack impedes
a standardized and systematic assessment of appropriateness and
quality of care using clinical development cycles.7 Motivated by the lack
of measurable elements for quality of care, we performed a structured
consensus process to define a final set of clinically relevant GBIs that
can be implemented in the daily care of adult MDS patients.
Methods
We applied a modified Research and Development Corporation
(RAND) technique with a 2-step DELPHI rating process (first round,
October 2018 to January 2019; second round, March 2019 to June
2019) to find an expert consensus on clinically relevant GBIs
(supplemental Figure 1).23-25
Screening of published G/Rs
The core working group (K.S., T.S., J. Bohlius, G.S., D.S., N.B.)
identified and screened evidence-based G/Rs and extracted all
relevant information (supplemental Table 1).26 With regard to MDS
diagnosis and therapy, we retrieved all information for potential
GBIs from 11 clinically relevant G/Rs published by national and
international MDS working groups between 2011 and 2018
(Table 1 G/Rs from clinical MDS working groups [n 5 11]).
Because aspects of provider/infrastructural characteristics were
not sufficiently addressed in clinical MDS G/Rs, all information for
this domain was extracted from an additional 6 guiding documents
published by national and international cancer care certification and
accreditation boards between 1999 and 2018 (Table 1 G/Rs from
cancer care certification/accreditation programs [n 5 6]).
Designation of multidisciplinary EPG members
The multidisciplinary expert panel group (EPG) included 28 and
27 members for the first and second rating rounds, respectively,
and comprised acknowledged MDS experts (hematologists), health
professionals with hemato-oncological expertise in their field (nursing,
pharmacology, physiotherapy, psycho-oncology, epidemiology), and
MDS patient advocates (Table 2). Experts were identified by the core
project working group upon recommendation from chairs of
medical or other health professional societies and were selected
according to modified European Consortium for Accreditation
criteria (supplemental Table 2).27 Each EPG member signed
a participation agreement and disclosed any potential conflicts
of interest for the rating of candidate GBIs.
Elaboration, aggregation, and structured
representation of candidate GBIs
The core working group elaborated, aggregated, and structured all
relevant information extracted from G/Rs as candidate GBIs within
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a formalized handbook (supplemental Handbook). This book
represented the basis for the subsequent DELPHI rating pro-
cedure and included information on scope, aims, and applied
methodologies. Candidate GBIs contained basic information
(domain/subdomain, aims, grade of recommendation), definitions
(numerator, denominator, relevant time points for assessments,
source) and supplementary information (rationale, requirements,
and limitations to use) (supplemental Table 3). Depending on the
rating performance and feedback from EPG members in the first
rating round, candidate GBIs were adapted, merged, or dropped
for the second round. All relevant information, including perfor-
mance, feedback from EPG members, and comments from the
core project working group, was reported back to the panelists.
Rating process
Each candidate GBI was rated independently in a DELPHI process
by each EPG member using a secured web-based survey.28
Access was granted via a Web link distributed individually to each
EPG member. Rating was performed according to the RUMBA
criteria22:
c Relevance, the indicator is relevant and represents key aspects
of the quality of MDS patient management;
c Understandability, the indicator is clear, precise, and compre-
hensively defined;
c Measurability, data collection concerning the indicator in real-life
setting is possible and does not require excessive effort;
c Behavioral oriented, the indicator concerns an aspect of MDS
patient management that can be targeted by service providers at
the personal or institutional level; and
c Attainability, the indicator’s goal is realistic and achievable under
given conditions.
A 9-point Likert-like scale was used for rating, yielding a maximum
score of 45 points per GBI. Each RUMBA criterion could be rated
from 1 (do not agree) to 9 (totally agree), where tertiles 1 to 3
represent “no agreement,” 4 to 6 “unclear,” and 7 to 9 “agreement.”
Individual ratings were kept anonymous to all others, but all
panelists received the aggregated information for each GBI after
the first and second rating round. Nonexperts in a given field could
Table 1. Guidelines and recommendations screened
Year Countries Institution Links and references
G/Rs from clinical MDS working
groups, n 5 11
Annual updates USA NCCN https://www.nccn.org/professionals/physician_gls/default.aspx#site
2018 Germany, Austria,
Switzerland
DGHO, OeGHO,
SGH-SHH
https://www.onkopedia.com/de/onkopedia/guidelines/myelodysplastische-syndrome-mds/@@
guideline/html/index.html
2017 Scandinavia NMDSG https://www.nmds.org/index.php/guidelines
2015 France GFM http://www.gfmgroup.org/recommandations.php
2017 Europe EBMT, ELN, BMT-
CTN
Allo-HSCT for MDS and CMML: recommendations from an international expert panel50
2014 Europe ESMO European Society for Medical Oncology MDS guidelines51
2013 Europe ELN European LeukemiaNet MDS guidelines52
2013 The Netherlands/
Belgium
HOVON https://hematologienederland.nl/kwaliteit/richtlijnen/
2013 UK BCSH British Committee for Standards in Haematology MDS guidelines53
2012 Spain GESMD https://www.gesmd.es/
2011 Italy FISiM https://www.fismonlus.it/en/about-fism/
G/Rs from cancer care certification/
accreditation programs, n 5 6
Annual updates UK NICE https://pathways.nice.org.uk/pathways/blood-and-bone-marrow-cancers#path5view%3A/
pathways/blood-and-bone-marrow-cancers/blood-and-bone-marrow-cancers-overview.
xml&content5view-index
2018 Germany DKG https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/deutsche-krebsgesellschaft/
zertifizierung/erhebungsboegen/onkologische-zentren.html
2017 USA ASCO/QOPI https://practice.asco.org/quality-improvement/quality-programs/qopi-certification-program
2016 USA ACS/CoC https://www.facs.org/quality-programs/cancer/coc/standards
2013 Switzerland SCN https://www.sgmo.ch/qualitaetssicherung/dokumentation/
1999 Europe OECI/ACOE http://www.acoe.be/About-ACOE/Mission-and-Objectives
ACOE, Accreditation Council for Oncology in Europe; ACS/CoC, American College of Surgeons/Commission on Cancers; BCSH, British Committee for Standards in Haematology;
BMT-CTN, Blood and Marrow Transplant Clinical Trials Network; CMML, Chronic myelomonocytic leukemia; DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie; DKG, Deutsche
Krebs Gesellschaft; EBMT, European Society for Blood and Marrow Transplantation; ELN, European Leukemia Net; ESMO, European Society of Medical Oncology; FISiM, Fondazione
Italiana Syndromi Mielodysplastice; GESMD, Groupo Espanol De Sindromes Mielodisplasticos; GFM, Groupe Francophone des Myelodysplasies; HOVON, Hemato Oncology Foundation for
Adults in The Netherlands; NCCN, National Comprehensive Cancer Network; NICE, National Institute for Health and Care; NMDSG, Nordic MDS Study Group; OECI, Organization of
European Cancer Institutes; OeGHO, Österreichische Gesellschaft für Hämatologie und Onkologie; SCN, Swiss Cancer Network; SGH-SSH, Swiss Society for Hematology; UK, United
Kingdom; USA, United States of America.
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skip the rating of candidate GBIs and free text boxes were offered
for general feedback. Additional subsurveys were included in
unclear situations and used to refine the definitions of GBIs.
Selection of GBIs
We used the following metrics for the evaluation of the rating
performance of each candidate GBI: (i) median score from all
RUMBA criteria; (ii) percentage from the maximum possible score
(% max score), representing the percentage of the sum of scores
divided by the maximum possible score; and (iii) agreement score
defined as the percentage of all numbers of ratings in tertile 7 to 9
(“agreement”) divided by the total number of ratings. Scores were
calculated for the overall rating performance (all RUMBA criteria
from all experts) as well as for each RUMBA item, MDS experts, and
non-MDS experts separately. In the first round, candidate GBIs
were ranked according to the less stringent criteria (i) and (ii),
keeping those with a median score $7 and percentage from the
maximum possible score $75%. In the second round, candidate
GBIs were ranked according to the more stringent criteria (iii)
(agreement score, tertile 7-9). GBIs from the diagnosis and therapy
domains with agreement scores $70% and GBIs from the
provider/infrastructural characteristics domain with agreement
scores $85% were selected for the final set of GBIs. Expert rating
disagreement was calculated as the difference of the agreement
scores between MDS and non-MDS experts, with a difference
.30% defined as relevant. To clarify definitions of some GBIs, we
used additional subsurveys, where we considered all ratings,70%
as not sufficiently relevant. We presented and discussed the final
set of GBIs at the European LeukemiaNet (ELN) annual meeting of
the MDS study group in Amsterdam on 11 October 2019.
Definitions for the use of GBIs
Definitions for the use of GBIs are summarized in supplemental
Table 4. We define disease-based risk according to the In-
ternational Prognostic Scoring System (IPSS) and revised IPSS
(IPSS-R); patients with IPSS-R intermediate are allocated to lower risk
if high-risk features are absent.29-34 Patient-based risk is determined by
the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI),
as it is most frequently used in clinical trials.35
Results
General aspects of the GBI selection process
The core working group extracted, elaborated, and aggregated
candidate GBIs from G/Rs in a formalized handbook. GBIs were
grouped in 3 main domains and assigned to appropriate
subdomains. This process resulted in 61 candidate GBIs for
diagnosis (n 5 23), therapy (n 5 21), and provider/infrastructural
characteristics (n 5 17), which entered the DELPHI rating pro-
cedure. The complete GBI selection process is summarized in
Figure 1. The feedback rates from themultidisciplinary EPGmembers
for the first and second DELPHI rounds were 82% (23 of 28) and
96% (26 of 27), respectively (Table 2). Feedback from non-MDS
experts was mainly given for the GBIs of provider/infrastructural
characteristics as well as GBIs for patient-reported outcomes
(PROs) and toxicity assessment (TA) (range, 50% to 90%)
(Table 3). Twenty-one candidate GBIs did not meet the less-
stringent selection criteria for the first rating round. Three GBIs
were rechallenged and 2 merged, leaving 42 candidate GBIs for
the second rating round.
Treatments can be inappropriate either by underuse or overuse.
Overtreatment was assessed by the EPG members for each GBI
from the therapy domain in the second rating round. To avoid the
generation of additional GBIs, overtreatment was integrated into the
corresponding GBI with an additional numerator (patients fulfilling
the aim of the GBI) and denominator (reference population). The
panelists considered only treatment with erythropoietin-stimulating
agents (ESAs), lenalidomide (LEN), and hypomethylating agents
(HMAs) at relevant risk for overtreatment.
Many GBIs from the provider/infrastructural characteristic domain
cover topics generally addressed by certification/accreditation
programs. However, some GBIs from this domain also measure
performance at the patient level. Additionally, as not all institutions
are certified/accredited, a minimal consensus on adequate in-
frastructure was defined for MDS management.
Diagnosis domain
For the diagnosis domain, 14 of 23 candidate GBIs were finally
selected after 2 rating rounds (Table 3). This domain comprises the
5 subdomains basic workup (n5 6), supplementary workup (n5 5),
diagnostic workup related to treatment (n 5 3), risk stratification
(n 5 5), and follow-up/outcomes (n 5 4). The agreement scores
(percentage of scoring in tertile 7-9) from each GBI in both rating
rounds are summarized as a radar plot in Figure 2A for the overall
and as a heat map in Figure 2B for each RUMBA item. All GBIs from
the subdomain basic workup were selected. Except for the GBI
molecular diagnostics/next-generation sequencing (NGS), most
GBIs from the subdomain secondary workup had to be dropped
after the first rating round. Immunophenotyping (IP) did not reach
sufficient agreement and was dropped after the first round, as
standardization, and its diagnostic and prognostic implications of
IP, seemed to be controversial. In the subdomain risk stratification,
the GBIs disease-based risk stratification according to IPSS and
disease-based risk stratification according to IPSS-R were merged
into 1 GBI after the first rating round. This was based on the
panelists’ feedback: they considered IPSS still relevant, as most
Table 2. Composition of EPG for the 2 DELPHI rating rounds
Expert panel group
First round Second round
Invited Participated Invited Participated
Hematologists 16 14* 17 16
Health professionals 7 6 7 7
Nurses 3 3 3 3
Pharmacologist 1 1 1 1
Physiotherapist 1 1 1 1
Psycho-oncologist 1 1 1 1
Epidemiologist 1 0 1 1
Patient advocates 5 3 3 3
Total 28 23 27 26
Feedback rate, % 82 96
Represented countries: Hematologists: Austria (2); Czech Republic (1); France (1);
Germany (2); United Kingdom (1); Greece (1); Israel (1); Italy (2); The Netherlands (2);
Portugal (1); Sweden (1); Switzerland (1); United States (1). Health professionals: The
Netherlands (2), Switzerland (5). Patient advocates: Denmark (1); Finland (1); Germany (1);
The Netherlands (1); United States (1).
*One with partial completion of the survey.
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Screening of published guidelines and recommendations:
elaboration, aggregation and structured representation of candidate GBIs in handbook
Domain 1:
Diagnosis
23 GBIs
Domain 2:
Therapy
21 GBIs
Domain 3:
Provider/infrastructural
characteristics 17 GBIs
1st rating round
Domain 1:
Diagnosis
8 dropped
2 merged into 1
2 kept for re-evaluation
Result: 16 GBIs
Domain 2:
Therapy
11 dropped
1 kept for re-evaluation
Result: 11 GBIs
Domain 3:
Provider/infrastructural
characteristics
2 dropped
Result: 15 GBIs
Domain 1:
Diagnosis
2 dropped
Result: 14 GBIs
Domain 2:
Therapy
3 dropped
Result: 8 GBIs
Domain 3:
Provider/infrastructural
characteristics 
8 dropped
Result: 7 GBIs
Final set of  29 GBIs
Domain 1: Diagnosis (n=14)
Diagnostic work-up:
- Cytogenetic analysis
- Bone marrow cytology/histology
- Peripheral blood assessment
- WHO 2016 classification
- Iron staining/monitoring
- Serum EPO in symptomatic anemia
- Molecular diagnostics/NGS
- TP53 in MDS del(5q)
Risk stratification:
- IPSS/IPSS-R
- Patient-based risk stratification
Follow-up/outcomes:
- Response assessment
- Patient-reported outcomes (PRO)
Domain 2: Therapy (n=8)
Supportive care:
- Transfusions of red blood cell
   concentrates
- Transfusions of platelet
   concentrates
Lower-risk:
- Erythropoietin stimulating agents
- Lenalidomide in MDS del(5q)
Higher-risk (unfit patients):
- Hypomethylating agents (HMAs)
Higher risk (fit patients):
- Induction before allo HSCT
   (blasts  10%)
- Up-front allo HSCT (blasts 5-10%)
- Allo HSCT  
Domain 3: Provider/
infrastructural characteristics
(n=7)
Personnel:
- Multidisciplinary care team
Organization:
- Safe handling of cytotoxic drugs
- Interdisciplinary diagnostic review
- Interdisciplinary treatment board
- Teaching and continuing
   education
- Emergency services
Cooperation:
- Access to clinical trials   
2nd rating round
Figure 1. Disposition and flow diagram of the
GBI selection process.
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clinical trials used it for treatment allocation, whereas IPSS-R was
found to be better for risk stratification.36 In the subdomain patient-
based risk stratification, the GBI assessment for germline pre-
disposition for inherited hematological malignancy syndromes did
not reach the agreement threshold in the first round, as it was not
considered sufficiently relevant, measurable, and attainable by the
EPG members at the time rating was performed. Finally, in the
follow-up/outcomes subdomain, all GBIs scored generally as highly
relevant but with a low agreement in measurability and behavioral
orientation, which affected their overall ranking (Figure 2B). The
GBIs monitoring of PROs and geriatric assessment (GA) did not
reach the required minimal agreement in the first round, as there
were controversies among experts on standardization and practi-
cability. As both are consistently found in G/Rs from national and
international MDS working groups, the core project working group
decided to keep them for reevaluation in the second DELPHI round.
The GBIs GA and TA finally had to be dropped, whereas PROs just
reached the required threshold of sufficient agreement after the
second rating round. In the expert rating agreement analysis, only
GA performed better in non-MDS than MDS experts, all others were
comparable (supplemental Figure 2).
Therapy domain
For the therapy domain, 8 of 21 candidate GBIs were finally
selected after 2 rating rounds (Table 3). This domain comprises the
3 subdomains supportive care (n5 6), lower risk (n5 9), and higher
risk (n 5 6), as defined in “Methods.” GBI agreement scores are
summarized as a radar plot in Figure 3A (overall) and as a heat map
in Figure 3B (each RUMBA item). In the subdomain supportive care,
only the GBIs transfusion of red blood cell concentrates and
transfusions of platelet concentrates reached sufficient agreement.
The GBI iron chelation (IC) had to be dropped after the second
round. Despite the panelists rating this GBI as relevant and
understandable, the behavioral aspect and the attainability seem to
be hampered by local guidelines, high treatment costs, fear of
adverse effects, and controversial clinical trial data. In the
subdomain lower risk and anemia, the GBIs ESAs and LEN in
MDS del(5q) reached sufficient agreement, whereas all others,
such as granulocyte colony-stimulating factor for ESA refractori-
ness, LEN in non-del(5q) as well as luspatercept in MDSwith ringed
sideroblasts or mutated SF3B1, had to be dropped after the first
rating round. None of the candidate GBIs in the subdomain other
cytopenias reached sufficient agreement. The GBI immunosup-
pressive treatment (IST) did not reach the required minimal
agreement in the first round. Because IST is also consistently
found in G/Rs from national and international MDS working groups,
it was kept for reevaluation in the second DELPHI round. The
performance also remained poor in the second round, as panelists
reported insufficient experience and standardization for treatment
of the rare lower-risk MDS patients with hypoplastic bone marrow.
The GBIs HMAs in higher-risk MDSs for unfit patients as well as
induction with chemotherapy or HMAs before allogeneic hemato-
poietic stem cell transplantation (allo-HSCT), upfront allo-HSCT,
and allo-HSCT (after induction chemotherapy) for fit higher-risk
MDS patients, respectively, reached sufficient agreement for
selection. GBIs defining procedures of postinduction chemother-
apy for patients without a suitable donor or complicated induction
course were dropped after the first rating round due to insufficient
evidence and lack of standardization. In the expert rating agreement
analysis, upfront allo-HSCT and IST performed better in MDS
than non-MDS experts, all others were comparable (supplemen-
tal Figure 3).
Provider/infrastructural characteristics domain
For the provider/infrastructural characteristics domain, 7 of 17
candidate GBIs were finally selected after 2 rating rounds (Table 3).
This domain comprises the 4 subdomains certification and
accreditation (n 5 2), personnel (n 5 3), organization (n 5 8), and
cooperation (n 5 4). GBI agreement scores are summarized as
a radar plot in Figure 4A (overall) and as a heat map in Figure 4B
(each RUMBA item). The higher selection threshold $85% was
justified based on the observation that most candidate GBIs
from this domain generally scored $70% and would have been
overrepresented in our final set of relevant GBIs. None of the
candidate GBIs from the subdomain certification and accreditation
was selected, as they were considered to be a mandatory
requirement for clinical practice outside of MDS management. In
the subdomain personnel, only the GBI multidisciplinary care team
reached the defined agreement threshold. Most GBIs from the
subdomain of organization reached the defined agreement, except
the GBIs isolation ward, multidisciplinary care board, and standard
operating procedures. For the subdomain cooperation, only the GBI
access to clinical trials was selected with high agreement. We
found a comparable expert rating agreement between MDS and
non-MDS experts in all GBIs of this domain (supplemental Figure 4).
Discussion
Here, we provide a first consensus on 29 clinically relevant GBIs for
diagnosis (n 5 14), therapy (n 5 8), and provider/infrastructural
characteristics (n5 7) for the care of adult MDS patients. Our GBIs
were extracted from published G/Rs and were selected by
a structured consensus process involving a multidisciplinary panel
with internationally recognized experts.
Surprisingly, some candidate GBIs, generally considered to address
relevant aspects of MDS care, did not meet the required threshold for
acceptance. These GBIs were uniformly rated as relevant but they
scored relatively low with regard to measurability, attainability, and/or
behavioral orientation. For those GBIs dropped in the diagnosis
domain (ie, IP, TA, and GA), there remains a need for improvement in
standardization, practicability as well as validation with future clinical
trials. For those dropped in the therapy domain (ie, IC and IST), there
are ongoing controversies on efficacy and toxicity as well as
insufficient agreement on their adequate use, especially for IST in
the rare entity of hypoplastic MDS. In the Swedish population-
based MDS registry, for instance, only 0.9% of MDS cases received
IST between 2009 and 2017, underlining the low frequency of this
MDS subtype and rare use of IST.37 Recently, a core outcome set
(COS) for MDS patients has been proposed by the ELN MDS
working group (COS-MDS). This set comprises overall survival
(OS), performance score (PS), hematological improvement (HI),
treatment-related mortality (TRM), safety, and quality of life (PROs).38
Except for TA (safety and TRM), all other outcomes are included in our
final set of GBIs. PROs reached the required threshold for acceptance
only after rechallenge in the second round. This underlines ongoing
controversies and the requirement for further improvements in
standardization, practicability, and validation of their clinical
utility. The rating performance of the selected GBIs was generally
similar between MDS and non-MDS experts (disagreement #30%).
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Only allo-HSCT performed better in MDS experts, suggesting a different
perception of its importance between the expert groups.
Currently, there is no generally accepted standard for the de-
velopment of GBIs. Our strategy may harbor some limitations, but the
applied methods are in line with approaches published by many
others.8,21 The appointment of EPGmembers and the preselection of
candidate GBIs can be potential sources of bias. Our selection of
internationally acknowledged MDS experts as well as multidisciplin-
ary non-MDS experts minimizes regional and discipline-associated
biases. The inclusion of non-MDS experts is in line with the current
recommendations for the development of GBIs. It stands to reason
that their opinion was most prominent for the GBIs from the structural
domain and for PROs, whereas for the other domains, most non-
MDS expert refrained from rating. Our EPG members were highly
committed (feedback rates, 82% and 96%, respectively) and also
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Figure 2. Rating performance of GBIs from the diagnosis domain. (A) Radar plot of overall GBI performance from the diagnosis domain showing agreement scores
from the first (blue curves) and second (red curves) DELPHI rating round. GBIs dropped after the first round are shown with single blue curve. (B) Agreement scores for each
GBI are shown as a heat map for overall and RUMBA subcategories for the first (left) and second (right) DELPHI rating round. GBIs are ranked according to the performance
in the second rating round with the selection threshold highlighted in a green dotted line at 70%. GBIs dropped after the first round are shown in gray for the second round.
GBIs selected, 14; merged, 2; dropped, 8.
4038 STOJKOV et al 25 AUGUST 2020 x VOLUME 4, NUMBER 16
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
provided general feedback. They did not suggest additional candidate
GBIs, indicating that we had covered all relevant aspects of MDS care
with our initial preselection. Our GBIs have been developed in the
context of high-income countries with mainly European experts. The
appropriateness of the selected GBIs for developing countries or other
countries, including the United States, not adequately represented by
the EPG members, may be debatable. As an example, HMAs may be
more frequently used in lower-risk MDS patients in the United States
compared with Europe, which is based on local differences of G/Rs.
We also think that assessment of germline predisposition in younger
MDS patients as well as treatment with luspatercept in MDS with
ringed sideroblasts/SF3B1mutations would have performed differently
today, as recent G/Rs are increasingly addressing germline pre-
disposition and luspatercept has recently been approved for anemic
0
10
20
30
40
50
60
70
80
90
100
Erythropoietin stimulating agents
Lenalidomide in MDS del(5q)
Allogeneic hematopoietic stem cell
transplantation
Transfusions of red blood cell
concentrates
Transfusions of platelet concentrates
Hypomethylating agents in higher-risk
MDS
Up-front allo HSCT
Induction with intensive chemotherapy
or HMA before allo HSCT
Over-treatment of asymptomatic,
lower-risk MDS patients
Immunosuppressive treatmentOvertreatment with growth-factors
Thrombopoietin stimulating agents
Granulocyte colony-stimulating factor
for ESA-refractoriness
Anti-bacterial prophylaxis
Post-induction chemotherapy for
patients without a suitable donor
Lenalidomide in non-del(5q) MDS
Hypomethylating agents in lower-risk
MDS
Granulocyte colony-stimulating factor
for infections
Post-induction HMAs for patients with
a complicated induction-course
Luspatercept in MDS with RS or
mutated SF3B1
Iron chelation second round
first round
70% threshold
A
B
Erythropoietin stimulating agents
Lenalidomide in MDS del(5q)
Allogeneic hematopoietic stem cell transplantation
Transfusions of red blood cell concentrates
Transfusions of platelet concentrates
Hypomethylating agents in higher-risk MDS
Up-front allo HSCT
Induction with intensive chemotherapy or HMA before allo HSCT
Over-treatment of asymptomatic, lower-risk MDS patients
Immunosuppressive treatment
Overtreatment with growth-factors
Thrombopoietin stimulating agents
Granulocyte colony-stimulating factor for ESA-refractoriness
Anti-bacterial prophylaxis
Post-induction chemotherapy for patients without a suitable donor
Lenalidomide in non-del(5q) MDS
Hypomethylating agents in lower-risk MDS
Granulocyte colony-stimulating factor for infections
Post-induction HMAs for patients with a complicated induction-course
Luspatercept in MDS with RS or mutated SF3B1
round 1,2
Iron chelation
overall R U M B A
%
0-5
5-10
10-15
15-20
95-100
90-95
85-90
80-85
75-80
70-75
65-70
60-65
55-60
50-55
45-50
40-45
35-40
30-35
25-30
20-25
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MDSpatients with ringed sideroblasts/SF3B1mutations.39,40 As such,
the selection of GBIs remains time-dependent and influenced by
regional preferences. Nonetheless, our set represents a first consen-
sus, which can be complemented with additional GBIs that were
currently not included and may be perceived to be relevant in other
contexts. The development of GBIs should remain dynamic, follow
future revisions of G/Rs, and need to be adapted at regular intervals.
Finally and most importantly, GBIs will never replace common sense,
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as it is virtually impossible to cover all aspects of irrational behavior,
including unnecessary repetition of diagnostic procedures. In any case,
our GBIs need future validation for operability and applicability in the
daily clinical care of MDS patients and investigations on their impact on
patient-centered outcomes. This is planned with the prospective,
observational I-CARE for MDS study (SAKK 33/18), which has
recently started and will be performed in collaboration with other
international MDS study groups.
Assessment of quality in the real-world setting of MDS patient care
has thus far not received adequate attention. Available data from
retrospective studies indicate common shortcomings in both
diagnostic workup and treatment.19 The analysis of a US Medicare
cohort of 4575 MDS patients diagnosed between 2006 and 2011
revealed that only 74% received a bone marrow cytogenetics
analysis.41 Several European population-based registries and MDS
cohorts published very similar results.36,42-45 The lack of cytoge-
netics impedes appropriate risk calculation by IPSS or IPSS-R.
Our set of GBIs includes all diagnostic methods required for
diagnosis and risk stratification and can be used to maintain and
improve diagnostic quality.16,29,30,34 Unexpectedly, IP did not reach
sufficient agreement, as it seems to be increasingly replaced by
NGS in cases of unclear diagnoses. Sequencing-based methods
are more reproducible and provide additional prognostic informa-
tion. However, standardization of NGS is ongoing and the clinical
benefit remains controversial.46,47 Determining the iron status and
the endogenous erythropoietin (EPO) level before starting anemia
treatment are 2 additional GBIs that were selected. According to
reports from the US Medicare cohort and the MDS registry from the
Fondazione Italiana Sindromi Mielodisplastiche (FISiM), iron status
was measured in 56% and endogenous EPO level in 43% of
patients receiving ESAs, respectively.41 These findings imply that
approximately one-half of all lower-risk MDS patients are treated
without knowing their chance for a response to ESAs.43,48
Allo-HSCT and HMAs are used in fit and unfit higher-risk MDS
patients, respectively. Both treatment modalities are included in our
final selection of GBIs. Of note, recent retrospective data from the
Italian FISiM registry reported that ;6% of eligible higher-risk MDS
patients were transplanted and 36% received HMAs, respec-
tively.43 Reasons for this remarkable underuse need to be explored.
A recent prospective and retrospective analysis of MDS patients
treated in a tertiary care center in Germany showed that adherence
to allo-HSCT G/Rs resulted in improved survival, whereas
adherence to other treatments did not.49 These data underscore
the impact of allo-HSCT G/Rs on survival, whereas the benefit of
less-intensive treatments on additional patient-centered outcomes
remains difficult to be captured in post hoc studies.
As in many other cancers, the number of MDS patient cases and
treatment-associated costs are continuously rising. This phenom-
enon coincides with increasing regulatory mandates that require
a culture of self-examination and quality improvement to maintain
value with optimized patient-centered outcomes. Such develop-
ments are fostered by the QOPI program initiated by ASCO.9
Therefore, our GBIs address an unmet clinical need and provide an
instrument for the systematic and standardized assessment of
guideline-based adherence in adult MDS patients. This instrument
will enable the comparison of quality of care in different health care
environments and the identification of potential areas for improve-
ment. Our GBIs represent the first comprehensive consensus of
measurable elements addressing best practice performance, out-
comes, and structural resources. They can be used as a standard-
ized instrument with the goal of assessing, comparing, and fostering
good quality of care within clinical development cycles in the daily
care. This first set of GBIs can be considered as a starting point for
more objective evaluation of quality of care in adult MDS patients. It
might not be ideal from the individual physician’s perspective,
however, it is the best compromise that can currently be achieved.
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A.G.D., C.E., S.E., P.F., U.G., M. Haschke, E.H.-L., M. Heger,
A.A.v.d.L., J.P., M.P., U.P., L.M., A.M.d.A., M.M., C. Morgenthaler,
D.P.S., V.S., R.S., A.S., and T.d.W. gave GBI ratings and critically
revised the paper; C. Maddox and T.d.W. provided essential sup-
port to the study and critical revision of the paper; S.S. performed
statistical analysis, provided graphs, and critically revised the paper;
G.S., D.S., and J. Bohlius designed the study, analyzed data, and
wrote the paper; and N.B. initiated and designed the study, analyzed
data, and wrote the paper.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests for the rating and selection of GBIs described
in this manuscript. Potentially perceived conflicts of interest
according to the definitions and terms of the International Com-
mittee of Medical Journal Editors are as follows: P.F. received
honoraria and research funding from Celgene Corporation, Jazz
Pharmaceuticals, and Astex, and research funding from Aprea. U.G.
received honoraria and research funding from Novartis and Cel-
gene, and honoraria from Jazz Pharmaceuticals and Amgen. M.
Haschke provided consultancy services to, and held membership
on an entity’s board of directors or advisory committees for, Sanofi
Aventis. A.A.v.d.L. received honoraria and research funding from
Celgene; research funding from Roche and Alexion; and honoraria
from Novartis and Pfizer. M.P. received honoraria from Janssen-
Cilag, and provided consultancy services to, and received honoraria
from, Novartis and Celgene. U.P. provided consultancy services to,
and received honoraria from, Celgene, AbbVie, and Novartis.
A.M.d.A. was on speaker’s bureaus for Celgene and Novartis. M.M.
received honoraria and research funding from, and was on
a speaker’s bureau for, Novartis. A.S. held membership on an
entity’s board of directors or advisory committees for, and received
research funding from, Merck Sharp & Dohme, Gilead, Takeda,
Janssen, Novartis, and Roche; received research funding from
Sanofi and Pfizer; and received honoraria and research funding
from, and held membership on an entity’s board of directors or
25 AUGUST 2020 x VOLUME 4, NUMBER 16 GUIDELINE-BASED INDICATORS FOR MDS 4041
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
advisory committees for, Celgene. D.P.S. received research funding
(to institution, not investigator) from H3 Biosciences; provided
consultancy services to Stemline, Pfizer, Onconova, Astex, and
Summer Road; held equity ownership in Arrowhead; and received
research funding from Aprea. V.S. received honoraria fromMenarini,
Amgen, Johnson & Johnson, Novartis, Pfizer, and Takeda; and re-
ceived honoraria and institutional research funding from Celgene
Corporation. R.S. received honoraria from, and held membership on
an entity’s board of directors or advisory committees for, Novartis;
received honoraria and research funding from Teva (Ratiopharm);
and provided consultancy services to, received honoraria and re-
search funding from, held membership on an entity’s board of
directors or advisory committees for, and was on an advisory board
for Celgene. T.d.W. received research funding from Novartis, Cel-
gene, and Amgen. N.B. receives research funding (to institution, not
investigator) from Astellas, Celgene, Novartis, Servier, and Sandoz;
and received financial support for travel from Amgen, Celgene,
Janssen, Novartis, Roche, and Sanofi. The remaining authors de-
clare no competing financial interests.
A complete list of the members of the Swiss MDS Study Group
and participating centers in the I-CARE for MDS (SAKK 33/18)
study can be found at www.MDS-Switzerland.ch. More information
on SAKK and the I-CARE for MDS (SAKK 33/18) study can be
found at www.sakk.ch/de/krebsarten/leukemias.
ORCID profiles: G.S., 0000-0002-1667-0637; D.S., 0000-
0001-8668-3065; S.E., 0000-0002-7379-7343; J.P., 0000-0001-
7092-3351; D.P.S., 0000-0001-5130-9284; R.S., 0000-0002-
8993-9561; A.S., 0000-0002-3685-3473; N.B., 0000-0001-
8761-2066.
Correspondence: Nicolas Bonadies, Department of Hematology
and Central Hematology Laboratory, Inselspital, Bern University
Hospital, University of Bern, Freiburgstr 18, CH-3010 Bern, Swit-
zerland; e-mail: nicolas.bonadies@insel.ch.
References
1. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342(8883):
1317-1322.
2. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA; The Cochrane Effective Practice and Organization of Care Review Group. Closing
the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ.
1998;317(7156):465-468.
3. Lawrence M, Olesen F. Indicators of quality in health care. Eur J Gen Pract. 1997;3(3):103-108.
4. Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Qual Saf Health
Care. 2009;18(5):385-392.
5. Shapiro DW, Lasker RD, Bindman AB, Lee PR. Containing costs while improving quality of care: the role of profiling and practice guidelines. Annu Rev
Public Health. 1993;14:219-241.
6. Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477-2481.
7. Califf RM, Peterson ED, Gibbons RJ, et al; American Heart Association. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol.
2002;40(11):1895-1901.
8. Shekelle PG. Quality indicators and performance measures: methods for development need more standardization. J Clin Epidemiol. 2013;66(12):
1338-1339.
9. Chiang AC. Why the quality oncology practice initiative matters: it’s not just about cost. Am Soc Clin Oncol Educ Book. 2016;35:e102-e107.
10. Kowalski C, Schulte H, Wesselmann S. Reporting program for cancer care quality indicators. J Oncol Pract. 2015;11(2):158-160.
11. Wennekes L, Ottevanger PB, Raemaekers JM, et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin’s
lymphoma. J Clin Oncol. 2011;29(11):1436-1444.
12. Wood L, Bjarnason GA, Black PC, et al. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal
cell carcinoma. J Oncol Pract. 2013;9(5):e262-e267.
13. Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol. 2003;21(10):1928-1936.
14. Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators.
J Clin Oncol. 2009;27(32):5445-5451.
15. Greenberg PL. Myelodysplastic syndromes: dissecting the heterogeneity. J Clin Oncol. 2011;29(15):1937-1938.
16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood. 2016;127(20):2391-2405.
17. Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272-281.
18. Bonadies N, Feller A, Rovo A, et al; NICER Working Group. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland
between 2001 and 2012. Cancer Epidemiol. 2017;46:85-92.
19. Frosch ZA, Abel GA. Assessing quality of care for the myelodysplastic syndromes. Curr Hematol Malig Rep. 2016;11(6):402-407.
20. Campbell SM, Braspenning J, Hutchinson A, Marshall M. Research methods used in developing and applying quality indicators in primary care.Qual Saf
Health Care. 2002;11(4):358-364.
21. Kötter T, Blozik E, Scherer M. Methods for the guideline-based development of quality indicators–a systematic review. Implement Sci. 2012;7(1):21.
4042 STOJKOV et al 25 AUGUST 2020 x VOLUME 4, NUMBER 16
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
22. Ketelaars CA. Using the RUMBA requirements in developing criteria. Nurs Qual Connect. 1994;4(2):7.
23. Chassin M. How do we decide whether an investigation or procedure is appropriate? In: Hopkins A, ed. Appropriate Investigation and Treatment in
Clinical Practice. London, United Kingdom: Royal College of Physicians; 1989.
24. Coulter I, Herman P, Ryan G, Hilton L, Hays RD; Members of CERC Team. The challenge of determining appropriate care in the era of patient-centered
care and rising health care costs. J Health Serv Res Policy. 2019;24(3):201-206.
25. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic
review. PLoS One. 2011;6(6):e20476.
26. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318(7183):593-596.
27. European Consortium for Accreditation. ECA Principles for the Selection of Experts. http://ecahe.eu/w/images/1/11/Eca-principles-for-the-selection-of-
experts.pdf. Accessed 10 January 2018.
28. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners.
J Biomed Inform. 2019;95:103208.
29. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):
2079-2088.
30. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):
2454-2465.
31. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Blood. 2014;124(9):1513-1521.
32. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
33. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic
stem-cell transplantation. J Clin Oncol. 2014;32(25):2691-2698.
34. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic
syndromes. J Clin Oncol. 2009;27(5):754-762.
35. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before
allogeneic HCT. Blood. 2005;106(8):2912-2919.
36. Moreno Berggren D, Folkvaljon Y, Engvall M, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting:
a report from the Swedish MDS register. Br J Haematol. 2018;181(5):614-627.
37. Regionala Cancercentrum SYD. Kvalitetsregisterrapporter MDS. https://www.cancercentrum.se/syd/cancerdiagnoser/blod-lymfom-myelom/
myelodysplastiskt-syndrom-mds/kvalitetsregister/rapporter/. Accessed 11 January 2019.
38. Rochau U, Stojkov I, Conrads-Frank A, et al. Development of a core outcome set for myelodysplastic syndromes—a Delphi study from the EUMDS
Registry Group. Br. J. Haematol. doi:10.1111/bjh.16654
39. University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies.
Blood. 2016;128(14):1800-1813.
40. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140-151.
41. Abel GA, Cronin AM, Odejide OO, Uno H, Stone RM, Steensma DP. Influence of patient and provider characteristics on quality of care for the
myelodysplastic syndromes. Br J Haematol. 2016;173(5):713-721.
42. Gattermann N, Kündgen A, Kellermann L, Zeffel M, Paessens B, Germing U. The impact of age on the diagnosis and therapy of myelodysplastic
syndromes: results from a retrospective multicenter analysis in Germany. Eur J Haematol. 2013;91(6):473-482.
43. Santini V, Della Porta M, Enrico B, et al Evaluation of adherence to treatment recommendations according to Italian and European guidelines in MDS
patients enrolled in the Italian FISiM Registry. In: Proceedings from the 15th International Symposium on Myelodysplastic Syndromes; 8-11 May 2019;
Copenhagen, Denmark.
44. Dinmohamed AG, van Norden Y, Visser O, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of
myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res. 2015;39(2):177-182.
45. Dinmohamed AG, Visser O, Posthuma EFM, et al. MDS classification is improving in an era of the WHO 2016 criteria of MDS: a population-based
analysis among 9159 MDS patients diagnosed in the Netherlands. Cancer Epidemiol. 2017;50(pt A):137-140.
46. Thol F, Platzbecker U. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Adv. 2019;3(21):3449-3453.
47. Sanz GF, Ibañez M, Such E. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Adv. 2019;3(21):
3454-3460.
48. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of
myelodysplastic syndromes with erythropoietin1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):
1037-1046.
49. Kasprzak A, Nachtkamp K, Kondakci M, et al. Combined retro- and prospective analysis of adherence to guidelines and patient-tailored therapeutic
recommendations in patients with myelodysplastic syndromes (MDS) at a tertiary care centre [abstract]. Blood. 2019;134(suppl 1). Abstract 4250.
50. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international
expert panel. Blood. 2017;129(13):1753-1762.
25 AUGUST 2020 x VOLUME 4, NUMBER 16 GUIDELINE-BASED INDICATORS FOR MDS 4043
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
51. Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMOGuidelinesWorking Group. Myelodysplastic syndromes: ESMOClinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii57-iii69.
52. Malcovati L, Hellström-Lindberg E, Bowen D, et al; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults:
recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-2964.
53. Killick SB, Carter C, Culligan D, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of adult
myelodysplastic syndromes. Br J Haematol. 2014;164(4):503-525.
4044 STOJKOV et al 25 AUGUST 2020 x VOLUME 4, NUMBER 16
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/16/4029/1756394/advancesadv2020002314.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 27 August 2020
